Novartis’s Xolair (omalizumab) Prefilled Syringe for Self-Injection Receives the US FDA’s Approval Across All Indications

 Novartis’s Xolair (omalizumab) Prefilled Syringe for Self-Injection Receives the US FDA’s Approval Across All Indications

Shots:

  • The US FDA has approved the sBLA for a new self-administration option for Xolair in patients across all approved indications in the US
  • The use of the therapy across multiple indications is based on the efficacy and safety profile of Xolair in allergic asthma, CIU, and nasal polyps, supported with a clinical development program, which includes 10 P- III studies
  • Xolair is the only FDA-approved biologic designed to target and block IgE. Genentech and Novartis work together to develop and co-promote Xolair in the US

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Bare Sky Marketing

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post